Novimp

Novimp is a French biotechnology company dedicated to developing innovative oncology treatments by targeting N-cadherin (CDH2), a key driver of tumor progression and resistance. Based in Marseille and founded as a spin-off from the University of Aix-Marseille, the company focuses on the Epithelial-Mesenchymal Transition (EMT) pathway to tackle aggressive solid tumors. Their primary therapeutic approach involves the development of monoclonal antibodies that inhibit N-cadherin-mediated signaling, which is often associated with metastasis and poor prognosis in cancers like triple-negative breast cancer and prostate cancer. Novimp's research aims to overcome current limitations in cancer therapy by providing targeted solutions for patients with high unmet medical needs.